Clinical Trial Update: The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial examining cellular immune adjuvant therapy for triple-negative breast cancer, sponsored by First Affiliated Hospital Xi'an Jiaotong University, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Cellular immune adjuvant therapy

Snippet

Sponsor: First Affiliated Hospital Xi'an Jiaotong University | Conditions: Triple Negative Breast Neoplasms | Phase 2 | Status: WITHDRAWN